Zealand Pharma A/S (ZLDPF) Discusses Top Line Phase II Results for ZUPREME-1 Trial of Petrelintide in Obesity Transcript

Core Viewpoint - Zealand Pharma announced positive top line results from the Phase II ZUPREME-1 trial of its amylin analog petrelintide, developed in partnership with Roche [2]. Group 1 - The conference call was led by Adam Lange, Vice President of Investor Relations, who welcomed participants and highlighted the significance of the trial results [2]. - The presentation included key figures and insights from the trial, with contributions from the company's leadership team, including the CEO and Chief Medical Officer [3].